The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Reversion of multidrug resistance by co-encapsulation of vincristine and verapamil in PLGA nanoparticles
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jain, R. A. (2000) · Biomaterials · doi:10.1016/s0142-9612(00)00115-0 · Cited by 2,214
Sahoo, S. K., & Labhasetwar, V. (2005) · Molecular Pharmaceutics · doi:10.1021/mp050032z · Cited by 340
Cited by
Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging
Parveen, S., Misra, R., & Sahoo, S. K. (2012) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2011.05.016 · Cited by 1,436
PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect
Acharya, S., & Sahoo, S. K. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.10.008 · Cited by 1,112
Polylactic acid (PLA) controlled delivery carriers for biomedical applications
Tyler, B., Gullotti, D., Mangraviti, A., Utsuki, T., & Brem, H. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.06.018 · Cited by 1,050
Nanoparticle-based combination therapy toward overcoming drug resistance in cancer
Hu, C.-M. J., & Zhang, L. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.01.008 · Cited by 686
Recent advances of cocktail chemotherapy by combination drug delivery systems
Hu, Q., Sun, W., Wang, C., & Gu, Z. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.10.022 · Cited by 625
“Typical nanocarriers in combination chemotherapy include polymeric nanoparticles[72, 73], liposomes[74, 75] and inorganic nanoparticles[76, 77].”
BackgroundNanotechnology-based combinational drug delivery: an emerging approach for cancer therapy
Parhi, P., Mohanty, C., & Sahoo, S. K. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.05.010 · Cited by 573
Nanotherapeutics to Overcome Conventional Cancer Chemotherapy Limitations
Chidambaram, M., Manavalan, R., & Kathiresan, K. (2011) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j30c7d · Cited by 566
Nanoparticle-assisted Combination Therapies for Effective Cancer Treatment
Hu, C.-M. J., Aryal, S., & Zhang, L. (2010) · Therapeutic Delivery · doi:10.4155/tde.10.13 · Cited by 564
PLGA-Based Nanoparticles as Cancer Drug Delivery Systems
Tabatabaei Mirakabad, F. S., Nejati-Koshki, K., Akbarzadeh, A., Yamchi, M. R., Milani, M., Zarghami, N., Zeighamian, V., Rahimzadeh, A., Alimohammadi, S., Hanifehpour, Y., et al. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.2.517 · Cited by 542
Nanoencapsulation of food ingredients using carbohydrate based delivery systems
Fathi, M., Martín, Á., & McClements, D. J. (2014) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2014.06.007 · Cited by 505
Nanomedicine for targeted cancer therapy: Towards the overcoming of drug resistance
Shapira, A., Livney, Y. D., Broxterman, H. J., & Assaraf, Y. G. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.01.003 · Cited by 504
Core–shell-type lipid–polymer hybrid nanoparticles as a drug delivery platform
Mandal, B., Bhattacharjee, H., Mittal, N., Sah, H., Balabathula, P., Thoma, L. A., & Wood, G. C. (2013) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2012.11.010 · Cited by 467
Recent progress in nanomedicine for enhanced cancer chemotherapy
Wei, G., Wang, Y., Yang, G., Wang, Y., & Ju, R. (2021) · Theranostics · doi:10.7150/thno.57828 · Cited by 463
Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents
Dinarvand, R., Sepehri, N., Manouchehri, Rouhani, & Atyabi, F. (2011) · International Journal of Nanomedicine · doi:10.2147/ijn.s18905 · Cited by 453
Progress in brain targeting drug delivery system by nasal route
Khan, A. R., Liu, M., Khan, M. W., & Zhai, G. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.09.001 · Cited by 402
Nanotechnology-based approaches in anticancer research
Kamal, M. A., Jabir NR, N., Tabrez, Ashraf, Shakil, & Damanhouri (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s33838 · Cited by 363
Nanopreparations to overcome multidrug resistance in cancer
Patel, N. R., Pattni, B. S., Abouzeid, A. H., & Torchilin, V. P. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.08.004 · Cited by 333
Co-delivery of siRNA and therapeutic agents using nanocarriers to overcome cancer resistance
Creixell, M., & Peppas, N. A. (2012) · Nano Today · doi:10.1016/j.nantod.2012.06.013 · Cited by 331
Fernandez-Fernandez, A., Manchanda, R., & McGoron, A. J. (2011) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-011-9383-z · Cited by 330
Customizing poly(lactic-co-glycolic acid) particles for biomedical applications
Swider, E., Koshkina, O., Tel, J., Cruz, L. J., de Vries, I. J. M., & Srinivas, M. (2018) · Acta Biomaterialia · doi:10.1016/j.actbio.2018.04.006 · Cited by 328
Nanotechnology applied to overcome tumor drug resistance
Gao, Z., Zhang, L., & Sun, Y. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.05.051 · Cited by 303
Multidrug resistance: Physiological principles and nanomedical solutions
Kunjachan, S., Rychlik, B., Storm, G., Kiessling, F., & Lammers, T. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.018 · Cited by 259
Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities
Kirtane, A. R., Kalscheuer, S. M., & Panyam, J. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.001 · Cited by 258
Nanodrug delivery in reversing multidrug resistance in cancer cells
Yergeri, M., Kapse-Mistry, S., Srivastava, R., & Govender, T. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00159 · Cited by 255
Banerjee, A., Pathak, S., Subramanium, V. D., G., D., Murugesan, R., & Verma, R. S. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.05.006 · Cited by 204
Duan, J., Mansour, H. M., Zhang, Y., Deng, X., Chen, Y., Wang, J., Pan, Y., & Zhao, J. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.01.020 · Cited by 194
“2008; Song et al., 2009; Kang et al., 2010; Dong et al., 2009; Wu et al., 2007; Tang et al., 2010; Dong and Mumper, 2010).”
Nanoformulations for combination or cascade anticancer therapy
Miao, L., Guo, S., Lin, C. M., Liu, Q., & Huang, L. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.06.003 · Cited by 178
“Other P-gp modulators, such as the first generation of P-gp inhibitor, verapamil [42], or the natural product extract, curcumin [43], can also inhibit P-gp pumps and sensitize cells to primary chemotherapeutic P-gp substrate, such as irinotecan [43], PTX [44], adriamycin [45, 46], and vinblastine[47].”
BackgroundRole of cellular uptake in the reversal of multidrug resistance by PEG-b-PLA polymeric micelles
Xiao, L., Xiong, X., Sun, X., Zhu, Y., Yang, H., Chen, H., Gan, L., Xu, H., & Yang, X. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.03.071 · Cited by 169
Metadata
- Authors
- Song, X. R., Cai, Z., Zheng, Y., He, G., Cui, F. Y., Gong, D. Q., Hou, S. X., Xiong, S. J., Lei, X. J., & Wei, Y. Q.
- Venue
- European Journal of Pharmaceutical Sciences
- Publisher
- Elsevier BV
- Published
- 2009-06
- Volume
- 37
- Issue
- 3-4
- Pages
- 300-305
- ISSN
- 0928-0987 (ISSN-L)
- OpenAlex
- W2090450679
- Cited by
- 211
- References
- 2
- FWCI
- 6.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.